Free Trial

Forte Biosciences (FBRX) Competitors

Forte Biosciences logo
$12.94 -0.95 (-6.84%)
Closing price 04:00 PM Eastern
Extended Trading
$12.93 -0.01 (-0.08%)
As of 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FBRX vs. OCS, OLMA, AKBA, ORKA, TYRA, PVLA, TBPH, TERN, NRIX, and GYRE

Should you be buying Forte Biosciences stock or one of its competitors? The main competitors of Forte Biosciences include Oculis (OCS), Olema Pharmaceuticals (OLMA), Akebia Therapeutics (AKBA), Oruka Therapeutics (ORKA), Tyra Biosciences (TYRA), Palvella Therapeutics (PVLA), Theravance Biopharma (TBPH), Terns Pharmaceuticals (TERN), Nurix Therapeutics (NRIX), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry.

Forte Biosciences vs. Its Competitors

Oculis (NASDAQ:OCS) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

Oculis has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 3.03, indicating that its stock price is 203% more volatile than the S&P 500.

Forte Biosciences has a net margin of 0.00% compared to Oculis' net margin of -13,958.12%. Forte Biosciences' return on equity of -85.38% beat Oculis' return on equity.

Company Net Margins Return on Equity Return on Assets
Oculis-13,958.12% -90.31% -67.85%
Forte Biosciences N/A -85.38%-72.34%

Oculis presently has a consensus target price of $41.00, suggesting a potential upside of 91.95%. Forte Biosciences has a consensus target price of $68.00, suggesting a potential upside of 425.50%. Given Forte Biosciences' higher possible upside, analysts plainly believe Forte Biosciences is more favorable than Oculis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oculis
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Forte Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Forte Biosciences has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oculis$780K1,195.61-$97.43M-$2.67-8.00
Forte BiosciencesN/AN/A-$35.48M-$16.29-0.79

22.3% of Oculis shares are held by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are held by institutional investors. 5.9% of Forte Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Oculis had 12 more articles in the media than Forte Biosciences. MarketBeat recorded 15 mentions for Oculis and 3 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 0.83 beat Oculis' score of 0.48 indicating that Forte Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oculis
3 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Forte Biosciences
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Forte Biosciences beats Oculis on 8 of the 14 factors compared between the two stocks.

Get Forte Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for FBRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FBRX vs. The Competition

MetricForte BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$172.69M$3.38B$6.11B$10.47B
Dividend YieldN/A2.29%5.73%4.77%
P/E Ratio-0.798.3264.8323.34
Price / SalesN/A488.16608.74136.45
Price / CashN/A46.7037.4661.86
Price / Book1.5810.5512.426.81
Net Income-$35.48M-$52.58M$3.32B$276.80M
7 Day Performance-9.95%1.09%1.01%0.27%
1 Month Performance12.72%16.09%10.75%8.31%
1 Year Performance180.09%18.41%76.20%35.60%

Forte Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FBRX
Forte Biosciences
2.834 of 5 stars
$12.94
-6.8%
$68.00
+425.5%
+196.2%$172.69MN/A-0.795
OCS
Oculis
2.9227 of 5 stars
$18.56
+5.6%
$35.75
+92.6%
+47.5%$767.15M$780K-6.952News Coverage
Analyst Revision
High Trading Volume
OLMA
Olema Pharmaceuticals
2.5541 of 5 stars
$11.06
-0.4%
$24.00
+117.0%
-8.4%$761.84MN/A-5.5970
AKBA
Akebia Therapeutics
3.4747 of 5 stars
$2.97
+4.9%
$6.75
+127.3%
+111.4%$750.36M$160.18M-17.47430News Coverage
ORKA
Oruka Therapeutics
3.0317 of 5 stars
$20.33
+2.7%
$42.00
+106.6%
-0.9%$741.16MN/A-7.23N/AAnalyst Forecast
TYRA
Tyra Biosciences
2.184 of 5 stars
$13.43
-1.7%
$31.86
+137.2%
-36.8%$728.04MN/A-7.5420High Trading Volume
PVLA
Palvella Therapeutics
2.0234 of 5 stars
$67.95
+3.3%
$69.27
+1.9%
N/A$727.51M$42.81M-5.62N/A
TBPH
Theravance Biopharma
3.0194 of 5 stars
$14.58
+1.2%
$23.00
+57.8%
+68.3%$725.70M$77.21M60.75110
TERN
Terns Pharmaceuticals
3.9223 of 5 stars
$8.43
+2.4%
$15.49
+83.7%
+6.0%$720.22MN/A-8.1140Analyst Forecast
NRIX
Nurix Therapeutics
1.8783 of 5 stars
$9.95
+6.1%
$29.07
+192.2%
-63.5%$717.09M$54.55M-3.81300Earnings Report
Analyst Forecast
GYRE
Gyre Therapeutics
1.7158 of 5 stars
$7.34
-0.9%
$18.00
+145.2%
-40.0%$713.68M$105.76M734.7340News Coverage
Gap Up

Related Companies and Tools


This page (NASDAQ:FBRX) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners